This approach is supported by a number of observations, including the identification of spontaneous mutant KRAS-specific T cells in PDAC patients (17); demonstrable efficacy of re-infused ex vivo expanded spontaneous CD8+ T cells recognizing KRAS G12D in an HLA-C*08:02 colorectal cancer patient (18); and autologous T cell transfer protocols using murine T cell receptors (TCRs) directed against HLA-A*11:01-restricted RAS G12D that could delay tumor growth in immune-deficient mouse xenograft models (19). This evidence concerns the gene KRAS and neoplasm.